|
ID
|
Factor description
|
Expression
|
|
Neublastin
(NsG1)
|
Mature Neublastin (Artemin) is a 113 aa member of the GDNF ligand family. Neublastin supports the survival of severeal peripheral neuronal population and works efficiently in animal models for neuropathic pain.
|
Neublastin is expressed at very low levels in the CNS but is found in the peripheral nervous system as well as a range of non-CNS tissues such as esophagus, larynx, parathyroid, stomach, prostate and lung
|
|
NsG6
|
NsG6 is a 98 aa secreted neurotrophic factor with potential therapeutic effects in diseases affecting cortical and midbrain areas as well as being a potential marker for certain types of testicular cancers.
|
NsG6 is transcriptionally regulated during development of cortex and substantia nigra. NsG6 is, however, most profoundly expressed in both mouse and human testis and significantly upregulated in testicular germ cell tumors.
|
|
NsG25
|
NsG25 is a protein that exists as two distinct isoforms. The mature isoforms are 361 aa and 246 aa secreted neurotrophic factors. NsG25 might have therapeutic value to diseases affecting hippocampus, such as Alzheimer’s disease or spinal cord injuries as well as being a marker for testicular abnormalities.
|
NsG25 is highly expressed in CNS and testis and developmentally regulated in mouse hippocampus and spinal cord.
|
|
NsG28
|
NsG28 belongs to the TAFA-family and the mature form is a 104 aa secreted neurotrophic factor with highly potential therapeutic effects in several neurological diseases such as Parkinson’s and Huntington’s disease as well as for certain types of stroke.
|
NsG28 is CNS specific and highly regulated during development of mouse nigra, cerebellum and thalamus. In human, NsG28 is most notably expressed in hypothalamus and thalamus.
In situ hybridisation data from E19 rat brain show high expression of NsG28 in habenular nucleus and medium high expression in paraventricular hypothalamic nucleus.
|
|
NsG29
|
NsG29 belongs to the TAFA-family and the mature form is a 105 aa secreted neurotrophic with a critical role in development of the central nervous system. NsG29 is considered a therapeutic factor for many neurological diseases.
|
NsG29 is transcriptionally regulated during development of many subregions of the mouse brain including hypothalamus, thalamus, cortex, midbrain (mesencephalon), cerebellum, pons, medulla, retina and spinal cord. Whereas the level of the NsG29 transcript remains high in adult cortex, its expression profile coincides with neuronal development in midbrain, medulla, pons and cerebellum.
|
|
NsG30
|
NsG30 belongs to the TAFA-family and the mature form is a 101 aa secreted neurotrophic factor with neuroprotective effects in PC12 cells.
NsG30 is considered a highly potential therapeutic factor for Parkinson’s and Huntington’s disease.
|
Expression of the NsG30 transcript is CNS specific and highly regulated during development of cortex, ventral and dorsal mesencephalon and pons. In situ hybridisation of NsG30 to rat brain at E19, P1 and P7 confirms the very high levels of NsG30 present in cortex.
|
|
NsG31
|
NsG31 is a protein that exists as two distinct isoforms. The mature isoforms are 139 aa and 103 aa secreted neurotrophic factors.
NsG31 is an interesting therapeutic candidate for peripheral neuropathies and retinopathies.
|
